ASL in Diagnostics of Tumor Progression Versus Radionecrosis in Brain Metastasis Following Gamma Knife Treatment

What this Trial Is About

This research aims to evaluate the use of arterial spin labeling (ASL), a non-invasive MRI technique, to help radiologists differentiate between brain metastasis progression and radionecrosis after gamma-knife treatment. The study focuses on assessing the diagnostic accuracy, including sensitivity and specificity, of quantitative ASL measures in patients with brain metastases suspected of progression or radionecrosis. The trial includes 60 patients in a prospective, single-center design. Participants will undergo three MRI scans: at baseline, one month, and six months after inclusion. The MRI includes ASL sequences for quantitative analysis of cerebral blood flow. Two neuroradiologists will independently and blindly analyze the MRIs to compare ASL's diagnostic performance with standard morphological MRI evaluations and T2 perfusion imaging. During the study, participants will attend an inclusion visit and follow-up visits at one and six months. Researchers will measure tumor perfusion using relative cerebral blood flow values from the ASL sequences across these time points. Secondary assessments include inter-reader agreement and morphological lesion analysis. The study monitors participants through these visits to gather imaging data and evaluate ASL's diagnostic utility in distinguishing tumor progression from radionecrosis.

ASL in Brain Metastasis MRI Following Gamma Knife Treatment